Arrowhead Pharmaceuticals vs Tarsus Pharmaceuticals
Arrowhead Pharmaceuticals is the larger business, with $829m of revenue in fiscal 2025 against $451m for Tarsus Pharmaceuticals (1.8 times as much). Arrowhead Pharmaceuticals grew faster (23258.2% against 146.7%). Arrowhead Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -0.2% against -14.7%.
| Latest fiscal year | Arrowhead PharmaceuticalsARWR, 2025 | Tarsus PharmaceuticalsTARS, 2025 |
|---|---|---|
| Revenue | $829m | $451m |
| Revenue growth | 23258.2% | 146.7% |
| Net income | −$1.6m | −$66.4m |
| Operating margin | — | -15.7% |
| Net margin | -0.2% | -14.7% |
| Return on equity | -0.5% | -23.4% |
| Free cash flow | $157m | −$22.3m |
| Cash | $227m | $184m |
| Total debt | $255m | $75.0m |
| Debt to equity | — | 21.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 711 | 370 |
| Market value | $8.43bn | $3.09bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 64 sales | 0 buys, 59 sales |